Cangrelor infusion is associated with an increased risk for bleeding: Meta-analysis of randomized trials

International Journal of Cardiology

Volumn 169, Issue 3, 2013, Pages 225-228

  Serebruany, Victor L ^a   Aradi, Daniel ^b   Kim, Moo Hyun ^a   Sibbing, Dirk ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Department of Cardiology   (Hungary)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bleeding; Cangrelor; Clinical trials; Safety

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; PLACEBO;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL ASSESSMENT TOOL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; INCIDENCE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RISK ASSESSMENT; TREND STUDY;

BLEEDING; CANGRELOR; CLINICAL TRIALS; SAFETY;

ADENOSINE MONOPHOSPHATE; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84887626924     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.133     Document Type: Article

References (18)

1. D.P. Chew, D.L. Bhatt, S. Sapp, and E.J. Topol Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials Circulation 103 2001 201 206
2. C.P. Cannon Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials Clin Cardiol 23 Suppl. 6:VI 2000 14 17
3. G. De Luca, C.M. Gibson, and F. Bellandi Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis Heart 94 2008 1548 1558
4. G. DE Luca, F. Bellandi, and K. Huber Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis J Thromb Haemost 9 2011 2361 2370
5. J.W. Eikelboom, S.R. Mehta, S.S. Anand, C. Xie, K.A. Fox, and S. Yusuf Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782
6. A.K. Rao, C. Pratt, and A. Berke Thrombolysis in myocardial infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1 1988 1 11
7. The GUSTO investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 10 1993 673 682
8. G.W. Stone, B.T. McLaurin, and D.A. Cox ACUITY investigators. Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
9. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
10. J.L. Ferreiro, M. Ueno, and D.J. Angiolillo Cangrelor: a review on its mechanism of action and clinical development Expert Rev Cardiovasc Ther 7 2009 1195 1201
11. D.J. Angiolillo, M.S. Firstenberg, and M.J. Price Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial JAMA 307 2012 265 274
12. R.A. Harrington, G.W. Stone, and S. McNulty Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
13. D.L. Bhatt, A.M. Lincoff, and C.M. Gibson Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
14. D.L. Bhatt, G.W. Stone, and K.W. Mahaffey Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 14 2013 1303 1313
15. R.C. Welsh, S.V. Rao, and U. Zeymer A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial Circ Cardiovasc Interv 5 2012 336 346
16. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
17. The FDA prasugrel secondary review Available for download at http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-00-FDA.htm (Assessed March 24, 2013)
18. FDA ticagrelor review of complete response - drug approval package http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000TOC.cfm (Assessed March 24, 2013)